Analysis of associations between polymorphic markers of the AGTR1 (A1166C), AGT (M235T), CYP11B2 (C-344T), AND ACE (I/D polymorphism) genes and the risk of developing hypotension in patients with newly diagnosed stage 1–2 hypertension after 3 weeks o

Objective: to determine the frequency of associations between polymorphic markers of the AGTR1 (A1166C), AGT (M235T), CYP11B2 (C-344T), ACE (I/D polymorphism) genes and the risk of developing hypotension in patients with newly diagnosed stage 1–2 hypertension after 3 weeks of pharmacotherapy with angiotensin II receptor blockers. Materials and methods: the study included 179 patients from the Moscow region with newly diagnosed stage 1–2 hypertension and low/moderate cardiovascular risk (CVD), of which 141 (78.8 %) were women and 38 (21.2 %) were men, aged from 32 to 69 years (mean age — 58.2 ± 6.4, median age 60 (57–63 years)). They were randomly assigned to treatment groups with valsartan or irbesartan according to CVD stratification. Results: no statistically significant association was found between the frequency of hypotension development and the AGTR1 A1166C genotype in patients receiving either irbesartan (p = 0.398) or valsartan (p = 0.179). No statistically significant association was found between the frequency of hypotension development and the AGT C4072T genotype in patients receiving irbesartan (p > 0.999), while the highest frequency of hypotension was observed in CC homozygotes receiving valsartan (p < 0.001). No statistically significant association was found between the frequency of hypotension development and the ACE genotype in patients receiving either irbesartan (p > 0.999) or valsartan (p = 0.149). No statistically significant association was found between the frequency of hypotension development and the CYP11B2 C344T genotype in patients receiving either irbesartan (p = 0.741) or valsartan (p = 0.14). Conclusion: the study results do not confirm a significant impact of the aforementioned genetic markers on the development of hypotension in response to ARB therapy.